ACRP CCRA COMPREHENSIVE
ASSESSMENT PAPER 2026 COMPLETE
QUESTIONS AND ANSWERS GRADED A+
●● Adverse event.
Answer: can therefore be any unfavourable and unintended sign
(including an abnormal laboratory finding), symptom, or disease
temporally associated with the use of a medicinal (investigational)
product, whether or not related to the medicinal (investigational) product
(see the ICH Guideline for Clinical Safety Data Management:
Definitions and Standards for Expedited Reporting)
●● Applicable Regulatory Requirement(s).
Answer: Any law(s) and regulation(s) addressing the conduct of clinical
trials of investigational products.
●● Approval (in relation to Institutional Review Boards).
Answer: The affirmative decision of the IRB that the clinical trial has
been reviewed and may be conducted at the institution site within the
constraints set forth by the IRB, the institution, Good Clinical Practice
(GCP), and the applicable regulatory requirements
●● Audit.
ASSESSMENT PAPER 2026 COMPLETE
QUESTIONS AND ANSWERS GRADED A+
●● Adverse event.
Answer: can therefore be any unfavourable and unintended sign
(including an abnormal laboratory finding), symptom, or disease
temporally associated with the use of a medicinal (investigational)
product, whether or not related to the medicinal (investigational) product
(see the ICH Guideline for Clinical Safety Data Management:
Definitions and Standards for Expedited Reporting)
●● Applicable Regulatory Requirement(s).
Answer: Any law(s) and regulation(s) addressing the conduct of clinical
trials of investigational products.
●● Approval (in relation to Institutional Review Boards).
Answer: The affirmative decision of the IRB that the clinical trial has
been reviewed and may be conducted at the institution site within the
constraints set forth by the IRB, the institution, Good Clinical Practice
(GCP), and the applicable regulatory requirements
●● Audit.
